Shortage reports
Actual shortage:
282 (8%)
Anticipated shortage:
15 (0%)
Avoided shortage:
11 (0%)
Resolved:
3369 (92%)
3677
Discontinuation Reports
To be discontinued:
24 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
366
143 (4%)
30 (9%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| MIRVALA 21 | 0.1500MG 0.0300MG | TABLET | Resolved | 2025-06-05 | 2025-07-12 | 259720 |
| MIRVALA 21 | 0.0300MG 0.1500MG | TABLET | Resolved | 2026-02-26 | 2026-04-13 | 279174 |
| MIRVALA 21 | 0.0300MG 0.1500MG | TABLET | Resolved | 2022-10-21 | 2022-11-07 | 172355 |
| MIRVALA 21 | 0.1500MG 0.0300MG | TABLET | Resolved | 2025-08-07 | 2025-08-15 | 264558 |
| MIRVALA 28 | 0.0300MG 0.1500MG | TABLET | Resolved | 2024-08-22 | 2024-10-18 | 235701 |
| MIRVALA 28 | 0.0300MG 0.1500MG | TABLET | Resolved | 2022-01-14 | 2022-01-18 | 152779 |
| MIRVALA 28 | 0.1500MG 0.0300MG | TABLET | Resolved | 2019-01-30 | 2019-04-26 | 74028 |
| MIRVALA 28 | 0.1500MG 0.0300MG | TABLET | Resolved | 2026-03-05 | 2026-04-21 | 279869 |
| MIRVALA 28 | 0.1500MG 0.0300MG | TABLET | Resolved | 2018-07-04 | 2018-07-12 | 54315 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2026-01-15 | 2026-02-23 | 276172 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2025-10-30 | 2025-11-07 | 270735 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2026-02-26 | 2026-03-06 | 279162 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2024-03-08 | 2024-03-15 | 221690 |
| MYA | 3.00MG 0.02MG | TABLET | Resolved | 2017-03-11 | 2020-09-04 | 555 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2025-05-08 | 2025-05-16 | 256899 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2023-05-26 | 2023-06-02 | 193206 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2023-09-22 | 2023-10-06 | 204996 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2023-12-15 | 2023-12-22 | 213568 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2025-02-20 | 2025-02-28 | 250925 |
| ONDANSETRON | 4MG | SOLUTION | Resolved | 2017-03-13 | 2017-03-31 | 2019 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 24MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110968 |
| APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |
| APO-HYDROMORPHONE CR | 4.5MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110974 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |